Ribo y Madrigal alcanzan un primer hito importante en el avance de nuevas terapias con siRNA para MASH

Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (hereinafter, "Ribo"), in collaboration with Madrigal Pharmaceuticals, Inc. (Madrigal, NASDAQ: MDGL ), have announced the achievement of the first candidate drug nomination milestone within their siRNA field alliance. This milestone is the result of an efficient collaboration and will pave the way for the immediate commencement of preclinical studies for the Investigational New Drug (IND) application to support planned clinical studies.

This alliance underscores Ribo and Madrigal's full joint commitment to advancing cutting-edge RNA therapies for liver diseases, with a primary focus on metabolic dysfunction-associated steatohepatitis (MASH), a field with enormous unmet medical needs. The collaboration covers multiple preclinical assets and further expands the potential therapeutic landscape targeting the liver for MASH.

"We are pleased to have achieved the first key milestone in our joint MASH program with Madrigal in just a few months. Madrigal has established a leading market position and possesses deep clinical expertise in the MASH field, while Ribo possesses world-class capabilities in siRNA drug discovery and delivery technology. Our complementary strengths serve to drive rapid progress in this project. Both parties are committed to accelerating the development of our novel siRNA candidate for MASH. We anticipate jointly advancing this collaboration program and providing new and promising therapeutic options to patients worldwide living with MASH," stated Li-Ming Gan, Ribo's Co-CEO and Global Head of R&D.